J&J Says CHMP Adopts Positive Opinion For Balversa (Erdafitinib) For Treatment Of Adult Patients
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Balversa (Erdafitinib) for the treatment of adult patients.
June 28, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Balversa (Erdafitinib) has received a positive opinion from the CHMP for the treatment of adult patients, which could lead to increased market approval and potential revenue growth.
The positive opinion from CHMP is a significant regulatory milestone that could lead to market approval in Europe, potentially increasing J&J's revenue from Balversa.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100